The gap between trailing and forward P/E suggests investors are capitalizing a recovery in the earnings base rather than paying for current profitability alone. A PEG of 1.59 sits above the 1.0 threshold typically associated with fairly priced growth, which may indicate the market is already embedding a meaningful portion of the expected acceleration. Relative to peers such as AMAT at 36.86 and LRCX at 32.15 on trailing earnings, KLAC is not obviously expensive, but ASML at 49.13 shows the premium the market assigns to pure lithography leadership, so KLAC appears to sit between cyclical equipment peers and the monopoly tier.

The narrow gross margin range points to durable pricing power in defect inspection, where tool necessity rather than price competition drives customer decisions. Operating margin expansion outpacing gross margin growth suggests R&D and SG&A are not scaling proportionally with revenue, which supports the view that incremental revenue is highly profitable. Net margin volatility, particularly the drop to 26.8% in 2025Q2 against a stable operating margin near 40%, warrants further investigation into non-operating or tax items before treating the 37% to 38% net margin of recent quarters as a clean run-rate.

The ROIC trajectory indicates improving efficiency of total invested capital, driven primarily by margin expansion rather than asset turnover, which remains low at roughly 0.2 times. ROE moderating despite rising ROIC is consistent with the equity base rebuilding after buybacks and leverage reduction, so the ROE decline should not be read as deteriorating business quality. Relative to LRCX at 65.2% ROIC and ASML at 84.2%, KLAC's ROIC is lower, which may reflect its heavier intangible and goodwill base rather than weaker operations.

The deleveraging appears driven mainly by equity expansion against a roughly flat debt load of $6.0B to $6.8B, so the improvement reflects a denominator effect rather than debt repayment. Debt-to-EBITDA of 3.06 remains moderate, though it has risen from 2.02 in 2024Q4 and merits monitoring given that EBITDA has been volatile across quarters. Investors should track whether coverage holds if earnings soften, since the recent gain in interest coverage is partly a function of rising operating income.